Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. - Wikidata - wikimedia - TriplyDB

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33388162

about

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Recent advancements in multimodality treatment of gliomas A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Molecular targeting of glioblastoma: Drug discovery and therapies Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Antiangiogenic therapy for glioblastoma: current status and future prospects.Glial progenitors as targets for transformation in glioma.The challenges and the promise of molecular targeted therapy in malignant gliomas.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma Combining molecular targeted agents with radiation therapy for malignant gliomas An update in the use of antibodies to treat glioblastoma multiforme.Strategies for optimizing the response of cancer and normal tissues to radiation.Current concepts in clinical radiation oncology.Anti-angiogenic therapy in glioma.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.Antiangiogenic therapies in glioblastoma multiforme.Therapeutic targeting of VEGF in the treatment of glioblastoma.Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Microenvironment and radiation therapy Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Bevacizumab for the treatment of glioblastoma.Targeted therapy in gliomas.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.Investigational new drugs for brain cancer.RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.New agents targeting angiogenesis in glioblastoma.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

P2860

Q26822717-A31DC745-1F94-44F1-8A3C-17F84359F6C5 Q27001724-608104DD-934A-407C-837E-32959082520C Q30300114-CB35F944-869F-4EA8-96DD-E63E4C0CA132 Q30764736-B331000A-DF9E-43FF-A96A-872547CEE384 Q33911283-0E09E333-443A-4532-B907-F4E9B90B6D56 Q34488803-B600B5AC-FBCE-4043-9EF3-FD1B0F190AF3 Q34515465-A73E67DB-A815-4E5E-AB1D-27D9D0AF083A Q34523319-BB3E2A6F-9F37-478C-B4F9-794E462FE777 Q34735661-170F5F27-834C-4270-A7AC-8DB68A877B99 Q35214534-34DB303F-62CE-4454-925D-C269EEC3B163 Q35895174-73A6B1FC-385B-4291-ACB3-70501E813046 Q36103026-3ECEF6B7-DABA-4041-A1D1-9B24E38802FF Q36526512-1598A0AF-631E-48A7-8F91-E801886ABA44 Q36792681-B655282E-3E42-4C43-915A-A47AAA9ABB4F Q37003332-9599964D-B6F5-4AFE-8636-2BED0D223907 Q37099594-EDCFBDAA-C647-4D8E-92ED-007BBAA74E35 Q37329927-3C99F01F-6A6C-4EE6-9172-FD96A9538EF8 Q37531724-FE51173E-03C7-4D93-9FAD-DFE82F94A5A3 Q37603804-9763C7B5-C5FB-45A5-9CAE-6E02846D8E8C Q37877409-A3A7937A-9C15-48E6-8D94-7BDBD710EC9F Q37952242-1C933324-256C-4B1B-8BCF-3DEF7A8E5849 Q38010802-0F0590B9-69F2-4D35-A237-3510FDB980A5 Q38033241-886A72C2-D799-4BD3-AC31-DE4C4D789518 Q38062793-F3A87E0F-95CA-4B1E-B9E9-12C812D187D5 Q38091084-8174C508-96D6-4882-9054-5E91BE3C0327 Q38108186-E5675AFF-79B3-4CFB-AEA6-E3769F4DC5BB Q38129428-02C50DA7-46D8-49EE-A3D5-BF80D9B26168 Q38186656-8179517B-D750-40E8-AFC0-6C102D721C6B Q38365290-928D4421-D698-428A-96BF-2F5FE099F98F Q38480274-310B362E-8766-4EAF-9066-340AD05EC360 Q38832510-FE16F046-F887-4DD6-AFF8-C7D14A6C81CB Q38973621-68A7797C-B7DB-46C5-86CB-683FF0BBB80B Q39137585-6F013D5C-2FA3-4874-9B87-552CCA340E85 Q39341824-86A80ABF-6A74-4AFD-94B2-D1E23644C0F0 Q39657781-F03A2FC2-E415-40B4-BFDD-1BAD6BD2EF3F Q41470815-F1257623-AD63-4312-917D-C613B76E96F6 Q46265366-83751F4C-5BDA-4224-A019-4070B2CEE3DF Q50091855-A1BBDB81-99FD-426F-82B2-176F10CC0588

P2860

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33388162

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@ast

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@en

type

label

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@ast

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@en

prefLabel

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@ast

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@en

P1433

Q33388162-DA4CB639-5E7F-4A78-B279-4B2D0198720E

P1476

Q33388162-89258D6D-EE78-454B-86AD-46C38BBB8C35

P2093

Q33388162-130EF6A8-6464-4297-9DD5-EA8AC27144CF

Q33388162-139D202E-D5DF-42C2-B494-AA15D8D157CA

Q33388162-3B5B07B6-200D-465B-A53C-4D617F80C7C4

Q33388162-406163F9-8DDD-4F73-A4F9-D9CBE1428890

Q33388162-458E5248-EDAB-4834-BD84-FEDACE2E532A

Q33388162-45CCE62E-F8D8-4EA3-AA65-8D717EE9D8EA

Q33388162-59CB1F31-1E2D-42B6-85C5-5DB12F79F315

Q33388162-5F739DAA-CCD9-46BE-9DC7-9E4A85AA2251

Q33388162-617026CC-FAE9-4854-A0DC-82561C4FBD8E

Q33388162-6CA65F81-CAC2-4216-B441-1FF3104A2293

P304

Q33388162-AC13FE15-410A-40D8-83E3-2556ADB9FF90

P31

Q33388162-C6E56A16-01F1-4D9E-87BC-EF193B3D2792

P356

Q33388162-56EF36F1-8109-4CA7-BC33-ACEFDDB6D51C

P407

Q33388162-5D8B2B9C-B354-4D60-BCF2-05C9844889DA

P433

Q33388162-C28A566B-C25A-4F70-8F3A-EEAD7B2E2FCF

P478

Q33388162-27490585-901A-477E-A66A-406C9731EAAE

P577

Q33388162-138E2DD5-3FA6-471D-B4E5-0F8CAD6DA39B

P5875

Q33388162-6C553E0A-A49D-44A3-85DB-D2ABD5344A10

P698

Q33388162-87834348-0FC2-4877-8420-6E486ACE8DD4

P921

Q33388162-E3FAA89D-4B7E-42EE-BDC5-C0C204857CE2

P356

J.IJROBP.2009.07.1741

P1433

International Journal of Radiation Oncology Biology Physics

P1476

Phase I study of vandetanib wi ...... newly diagnosed glioblastoma.

@en

P2093

Abigail Ciampa

http://www.w3.org/2001/XMLSchema#string

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Andrew D Norden

http://www.w3.org/2001/XMLSchema#string

Christine Sceppa

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Debra C Lafrankie

http://www.w3.org/2001/XMLSchema#string

Eric T Wong

http://www.w3.org/2001/XMLSchema#string

Geoffrey Young

http://www.w3.org/2001/XMLSchema#string

Jan Drappatz

http://www.w3.org/2001/XMLSchema#string

Keith L Ligon

http://www.w3.org/2001/XMLSchema#string

P304

85-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2009.07.1741

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41412380

http://www.w3.org/2001/XMLSchema#string

P698

20137866

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy